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a b s t r a c t 
Objectives: Colistin resistance in Acinetobacter spp. is increasing, resulting in potentially untreatable noso- 
comial infections. Plasmid-mediated colistin resistance is of particular concern due to its low fitness cost 
and potential transferability to other bacterial strains and species. This study investigated the colistin 
resistance mechanism in a clinical Acinetobacter nosocomialis isolate from Cape Town, South Africa. 
Methods: A colistin-resistant A. nosocomialis isolate was identified from a blood culture in 2017. PCR and 
Illumina whole-genome sequencing (WGS) were performed to identify genes and mutations conferring 
resistance to colistin. Plasmid sequencing was performed on an Oxford Nanopore platform. mcr function- 
ality was assessed by broth microdilution after cloning the mcr gene into pET-48b( + ) and expressing it 
in SHuffle® T7 Escherichia coli and after curing the plasmid using 62.5 mg/L acridine orange. 
Results: The colistin minimum inhibitory concentration (MIC) of the A. nosocomialis isolate was 16 mg/L. 
The mcr-4.3 gene was detected by PCR and WGS. No other previously described colistin resistance mech- 
anism was found by WGS. The mcr-4.3 gene was identified on a 24 024-bp RepB plasmid (pCAC13a). 
Functionality studies showed that recombinant mcr-4.3 did not confer colistin resistance in E. coli. How- 
ever, plasmid curing of pCAC13a restored colistin susceptibility in A. nosocomialis . 
Conclusion: We describe the first detection of a plasmid-mediated mcr-4.3 gene encoding colistin re- 
sistance in A. nosocomialis and the first detection of mcr-4.3 in a clinical isolate in Africa. Recombinant 
expression of mcr-4.3 did not confer colistin resistance in E. coli , suggesting that its functionality may be 
RepB plasmid-dependent or species-specific. 
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial 
Chemotherapy. 
This is an open access article under the CC BY-NC-ND license 

















Acinetobacter spp. has been increasingly reported as an op- 
ortunistic pathogen causing severe nosocomial infections, e.g. 
entilator-associated pneumonia, catheter-related bacteraemia, uri- 
ary tract, wound and soft-tissue infections, postsurgical endo- ∗ Corresponding author. Mailing address: Division of Medical Microbiology, Fac- 
lty of Medicine and Health Sciences, Stellenbosch University and NHLS, Tygerberg 
ospital, Francie van Zijl Drive, Tygerberg, P.O. Box 241, Cape Town 80 0 0, South 
frica. 








213-7165/© 2021 The Authors. Published by Elsevier Ltd on behalf of International Socie
Y-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) arditis and meningitis. Acinetobacter spp. infections are often diffi- 
ult to treat owing to multidrug resistance. Colistin is considered a 
ast-resort antimicrobial used to combat these infections; however, 
olistin resistance in Acinetobacter spp. has emerged worldwide, in- 
luding in South Africa [ 1 , 2 ]. 
In Acinetobacter spp., chromosomally-encoded colistin resis- 
ance mechanisms include mutations in the pmrB, pmrA and pmrC 
peron genes and in genes encoding lipid A biosynthesis ( lpxA, 
pxC and lpxD ). These mutations modify the lipid A of lipopolysac- 
haride (LPS) or lead to the complete loss of LPS [2–4] , thereby 
onferring colistin resistance. Integration of the insertion sequence 
S Aba11 in lpxC or lpxA also causes inactivation of LPS production ty for Antimicrobial Chemotherapy. This is an open access article under the CC 










































































































5] . Alternatively, overexpression of phosphoethanolamine trans- 
erase can result from the integration of IS AbaI upstream of a pmrC 
omologue ( eptA ), also leading to colistin resistance [6] . 
Colistin resistance due to plasmid-mediated mobile colistin re- 
istance genes mcr-1 to mcr-10 has been described worldwide in 
umerous bacterial species from various sources [7–10] . In Acine- 
obacter baumannii, mcr-1 and the mcr-4.3 variant have been de- 
cribed [11] ; however, there are conflicting data regarding the role 
f mcr-4.3 in colistin resistance [12–14] . New mcr variants are be- 
ng identified worldwide at an alarming rate, yet the functional 
ole of some of these variants is not clear. 
In South Africa, colistin resistance mechanisms have been inves- 
igated in Acinetobacter spp. [1] , but mcr genes have not yet been 
etected. mcr-1 has been identified in Escherichia coli and Kleb- 
iella spp. from clinical isolates in multiple hospitals [7–9] and in 
. coli isolated from broiler chickens, a pig and final effluents from 
astewater treatment plants [15–18] . The mcr-9.1 variant has been 
etected in Enterobacter hormaechei clinical isolates from South 
frica but was not associated with colistin resistance [19] . 
As colistin is one of the few ‘last-resort’ therapeutic options, it 
s important to elucidate and monitor the mechanisms contribut- 
ng to colistin resistance. Plasmid-mediated colistin resistance is of 
articular concern due to its low fitness cost and the potential for 
ransfer to other strains and species of bacterial pathogens. This 
tudy investigated the colistin resistance mechanism in a clinical 
cinetobacter nosocomialis isolate from Cape Town, South Africa. 
. Materials and methods 
.1. Isolate collection and clinical setting 
A single colistin-resistant A. nosocomialis isolate was obtained 
rom routinely collected clinical specimens processed at the Na- 
ional Health Laboratory Service (NHLS) laboratory at Tyger- 
erg Hospital in 2017. The isolate formed part of a larger co- 
ort of colistin-resistant Acinetobacter spp. isolates collected by 
onvenience sampling over a 16-month period (2016–2017) [1] . 
atrix-assisted laser desorption/ionisation time-of-flight (MALDI- 
OF) (Bruker Daltonik GmbH, Bremen, Germany) was used for 
pecies identification, and antibiotic susceptibility was initially de- 
ermined using a VITEK®2 Advanced Expert System TM . 
.2. Colistin susceptibility testing 
Colistin broth microdilution (BMD) and SensiTest TM Colistin (Li- 
filchem, Roseto degli Abruzzi, Italy) were performed following 
uropean Committee on Antimicrobial Susceptibility Testing (EU- 
AST) guidelines and breakpoints version 10 ( ≤2 mg/L, susceptible; 
 2 mg/L, resistant) [20] . Acinetobacter baumannii EUCAST-20 [min- 
mum inhibitory concentration (MIC), 0.5 mg/L] and E. coli NCTC®
3846 (MIC, 2–4 mg/L) were included as control strains. 
.3. PCR detection of mcr genes 
After culturing isolate CAC13 on blood agar, genomic DNA was 
xtracted using a crude boil–freeze extraction method [21] . PCR 
etection of mcr-1, -2, -3, -4 and -5 was performed as previously 
escribed [1] . The complete mcr-4 gene was amplified and se- 
uenced using previously published primers (Mcr-4 ext FW, 5 ′ -ATC 
GT TAA GTT TGT TGG TGA C-3 ′ ; and Mcr-4 ext R, 5 ′ -TGA GAG
TA AAT GTA ACA ATA GA-3 ′ ) [22] using previously described PCR 
eagents and mcr-1 amplification conditions [7] . Sanger sequencing 
as performed to confirm the mcr-4 amplicons. 103 .4. Whole-genome sequencing (WGS) 
WGS was performed as previously described [1] . Briefly, DNA 
as extracted using a Roche Pure PCR Template Preparation Kit 
Roche Diagnostics, Germany). The DNA concentration was deter- 
ined using a Qubit dsDNA BR Assay Kit and Qubit 2.0 Fluo- 
ometer (Life Technologies, USA) and the DNA was diluted to 0.2 
g/ μL. Library preparation was performed using a Nextera DNA 
lex Library Preparation Kit (Illumina, Germany) and sequencing 
as performed using a MiSeq Reagent Kit v.2 on an Illumina MiSeq 
esktop sequencer for 26 h to produce paired-end sequences. Se- 
uencing reads were assessed for sufficient coverage [ > 30 × based 
n mapping to reference genome A1 ( CP010781 )] and assembly 
tatistics ( N 50 > 10 0 0 0 0-bp; length ~4 M-bp; total number of
ontigs < 100) (Supplementary Table S1a). Taxonomic identifica- 
ion was done using Kraken v.0.10.5-beta with the 4GB MiniKraken 
atabase [23] . Assemblies were generated using SPAdes v.3.13.1 
24] and were annotated using Prokka v.1.14.0 [25] . 
Acquired antimicrobial resistance genes and mutations in the 
pxA, lpxC, lpxD, pmrA, pmrB and pmrC genes were detected 
sing ARIBA v.2.7.1 [26] , CARD v.3.1.0 [27] and ResFinder 4.0 
28] databases as previously described [1] . ISFinder ( https:// 
ww-is.biotoul.fr/blast.php ) was used to screen for insertion se- 
uence (IS) elements. Additionally, Artemis [29] was used to man- 
ally screen the annotated assemblies for known colistin resis- 
ance mutations and IS elements. The multilocus sequence typing 
MLST) ( https://github.com/tseemann/mlst ) server was used to de- 
ermine the sequence type (ST) based on WGS data using the Pas- 
eur scheme ( https://pubmlst.org ). 
.5. Oxford Nanopore plasmid sequencing 
Plasmid DNA was extracted using an alkaline lysis method 
pH 8) followed by phenol:chloroform:isoamyl alcohol extrac- 
ion (25:24:1) adapted from protocols from Addgene ( https:// 
ww.addgene.org/protocols/purify- plasmid- dna ) and IGEM (Inter- 
ational Genetically Engineered Machine 2015) (Supplementary 
rotocol 1). DNA library preparation was done using the 1D Native 
arcoding genomic DNA protocol with two kits: EXP-NBD104 and 
QK-LSK109 Kit R9 (Oxford Nanopore Technologies, Oxford, UK) ac- 
ording to the manufacturer’s protocol. Sequencing was performed 
sing a FLO-MIN106 flow cell on a MinION Mk1B sequencer with 
inKNOW software v.1.15.1 (Oxford Nanopore Technologies). 
Base calling and manual demultiplexing were performed us- 
ng Guppy v.3.4.3 [30] . Unicycler v.0.4.8 ( https://github.com/rrwick/ 
nicycler ) with dependencies (spades.py v.3.11.1, racon v.1.4.7, 
akeblastdb v.2.6.0 + , tblastn v.2.6.0 + , bowtie2-build v.2.3.4.1, 
owtie2 v.2.3.4.1, samtools v.1.4.1, java v.11.0.8 and pilon v.1.23 
or polishing) was used to hybridise the short Illumina and long 
anopore reads (Supplementary Table S1b). 
Bandage v.0.8.1 ( https://rrwick.github.io/Bandage/ ) [31] and 
GView Server ( http://cgview.ca/ ) with Prokka [25] annotation and 
asic Local Alignment Search Tool (BLAST) capabilities were used 
o visualise the plasmids. Acquired antimicrobial resistance genes 
ere detected using ARIBA [26] , CARD [27] and ResFinder 4.0 
28] databases. The genomic raw reads and assemblies from the 
llumina and Nanopore sequencing have been deposited in the 
ational Center for Biotechnology Information (NCBI) database ( 
RJNA665160 ) (Supplementary Table S1a). 
.6. Functional characterisation of the mcr-4.3 gene 
The entire mcr-4.3 coding sequence with Xho I and Nde I restric- 
ion sites was amplified using primers mcr-4YF (5 ′ -CAT ATG ATT 
CT AGA TTT AAG ACG TTA TC-3 ′ ) and mcr-4YR (5 ′ -CTC GAG CTA 
TA CCT GCA AG-3 ′ ) (IDT, USA) using a HIFI HotStart ReadyMix PCR 



















































































































it (Kapa Biosystems, South Africa) with 0.2 μM of each primer 
nd an annealing temperature of 56 °C. The mcr-1 gene was ampli- 
ed from NCTC® 13846 as a control using primers mcr-1YF (5 ′ -CAT 
TG ATG ATG CAG CAT ACT TCT GTG TGG TAC CG-3 ′ ) and mcr-1YR
5 ′ -CTC GAG TCA GCG GAT GAA TGC GGT-3 ′ ) using the same PCR 
onditions with an annealing temperature of 58 °C. 
The mcr genes were cloned into the Xho I and Nde I restric- 
ion sites of the pET-48b( + ) expression vector using a CloneJET 
CR Cloning Kit (Thermo Fisher Scientific, Difco Laboratories, USA) 
32] and were transformed into a colistin-susceptible SHuffle® T7 
ompetent E. coli strain [Inqaba Biotechnical Industries (Pty) Ltd., 
outh Africa]. Colonies were selected on Luria–Bertani (LB) agar 
lates supplemented with 15 mg/L kanamycin and the insert was 
onfirmed using PCR and Sanger sequencing. BMD was performed 
o assess the role of the mcr gene in colistin resistance. 
.7. Plasmid curing 
Plasmid curing of CAC13 was performed in triplicate with 62.5 
g/L acridine orange (Glentham Life Sciences Ltd., UK) in 0.2 mL 
f culture at a 0.5 McFarland standard as previously described [33] . 
erial dilutions (10 –1 –10 –4 ) were performed and 0.1 mL was plated 
n LB agar plates with and without 4 mg/L colistin, followed by 
vernight incubation at 37 °C. mcr-4 PCR and plasmid extraction, 
s mentioned above, were performed on colonies from both agar 
lates to detect the mcr-4.3 gene and pCAC13a plasmid, respec- 
ively. BMD was performed in triplicate to determine the colistin 
usceptibility of the plasmid-cured isolate. 
. Results 
A single colistin-resistant A. nosocomialis isolate (CAC13) was 
dentified from a larger study of colistin-resistant clinical Acineto- 
acter spp. in Cape Town, South Africa [1] . This isolate had a col-
stin MIC of 16 mg/L and was obtained from a blood culture from 
 patient at a district hospital in Cape Town in 2017. In addition 
o colistin resistance, this isolate was phenotypically resistant to 
efotaxime and trimethoprim/sulfamethoxazole but was suscepti- 
le to amikacin, cefepime, ceftazidime, ciprofloxacin, gentamicin, 
iperacillin/tazobactam and carbapenems based on VITEK®2 Ad- 
anced Expert System TM antimicrobial susceptibility testing. 
The mcr-4 gene was detected in CAC13 using PCR. Sanger se- 
uencing of the entire mcr-4 gene showed 100% amino acid iden- 
ity and coverage (430/430) to the mcr-4.3 allele and the sequence 
as deposited in GenBank ( MG948623 ). Based on WGS, CAC13 
as identified as ST279 and harboured no known colistin resis- 
ance mutations in the pmrBAC operon or lpx genes. 
Nanopore plasmid sequencing showed that mcr-4.3 was 
ncoded on a 24 024-bp plasmid (pCAC13a; GenBank 
ACYVX010 0 0 0 081.1 ) with > 50% coverage and < 98.85% iden- 
ity to mcr-4.3 -harbouring plasmids from other A. baumannii 
solates [12–14] ( Fig. 1 ). pCAC13a encodes the replication initiation 
rotein RepM from the RepB family, which is part of the Rep-3 
uperfamily (Pfam:01051), and is identical to a GR22 pAb-MCR4.3 
lasmid [13] . The plasmid also contains an IS 3 family transposase 
IS Aba19 ) and copies of two different type II toxin–antitoxin 
ystems (PhD/YefM and RelE/ParE) that are involved in plasmid 
tabilisation and maintenance. mcr-4.3 was found downstream of a 
utative recombinase family protein and a Tn 3 family transposase 
IS Psy42 ). No mobile elements were found downstream of the 
cr-4.3 gene. 
No additional antibiotic resistance gene were detected on 
CAC13a. However, an additional sulfonamide resistance gene 
 sul2 ) was detected on a separate 17 330-bp RepB plasmid 
pCAC13b; GenBank JACYVX010 0 0 0 080.1 ). 104 In E. coli , recombinant mcr-4.3 (in pET-48b) did not result in 
n increase in the colistin MIC, in contrast to the 8-fold increase 
n colistin MIC conferred by mcr-1 ( Table 1 ). The pCAC13a plasmid 
as cured from the A. nosocomialis isolate at an acridine orange 
oncentration of 62.5 mg/L. All colonies screened from the colistin- 
ontaining LB retained the pCAC13a plasmid containing the mcr- 
.3 gene, while colonies that were cultured on the LB-only agar 
lates were mcr-4.3 -negative and had lost the pCAC13a plasmid. 
he plasmid-cured A. nosocomialis isolate showed a 16-fold reduc- 
ion in MIC ( Table 1 ) in comparison with the parental strain. 
. Discussion 
This study investigated the colistin resistance mechanism in 
n A. nosocomialis clinical isolate from Cape Town, South Africa. 
he mcr-4.3 gene was detected on a 24 024-bp RepB plasmid 
pCAC13a). No other previously described colistin resistance mech- 
nisms and/or possible colistin resistance determinants, such as 
utations, insertions, deletions or stop codons in the pmrCAB or 
px genes, were identified. 
This study showed that recombinant mcr-4.3 does not confer 
olistin resistance in E. coli , however plasmid curing of the mcr- 
.3 -encoding pCAC13a plasmid restored susceptibility to colistin in 
. nosocomialis . There are conflicting data regarding the contribu- 
ion of mcr-4.3 to colistin resistance (Supplementary Table S2); two 
ther studies have also shown that recombinant expression of mcr- 
.3 in E. coli does not impact the colistin MIC [ 34 , 35 ], while one
as found the gene to result in colistin resistance [13] . Similar 
o this study, none of these studies confirmed the expression of 
cr-4.3 in E. coli . Therefore, the absence of a change in colistin 
IC might be attributed to the phosphoethanolamine transferase 
ot being expressed from the pET-48 plasmid in E . coli , rather 
han mcr4.3 not playing a role in colistin resistance. Alternatively, 
he native genomic environment of the plasmid may contribute 
o colistin resistance, and/or mcr-4.3 -mediated colistin resistance 
ay be species-dependent. For example, the native promoter and 
egulatory elements involved in mcr-4.3 expression may be spe- 
ific to Acinetobacter . This is supported by reports that in Acineto- 
acter spp., the mcr-4.3 gene has only been detected in colistin- 
esistant isolates, while in Shewanella frigidimarina and Leclercia 
decarboxylata, mcr-4.3 has been detected in colistin-susceptible 
solates [ 12 , 36 ]. In Acinetobacter spp., mcr-4.3 has always been de- 
ected on a RepB plasmid, which is in contrast to the mcr-4.3 genes 
n other hosts, which were all harboured on ColE10-type plasmids 
34–36] or were chromosomally-encoded [12] . Therefore, the activ- 
ty of the mcr-4.3 gene may be dependent on other factors encoded 
n the RepB plasmid, which may alter its expression or modify the 
xpressed protein to cause colistin resistance. There could also be 
n alternative colistin resistance mechanism encoded on pCAC13a 
ausing colistin resistance, although no potential candidates were 
dentified by plasmid sequencing and annotation. 
Plasmid-mediated colistin resistance is a major threat due to 
ts low fitness cost and ability to be transferred between dif- 
erent strains and species. No conjugation-related open-reading 
rames were detected on the pCAC13a plasmid, which is consis- 
ent with other mcr-4.3 plasmids (pEH_mcr4.3, pEC_mcr4.3 and 
AB18PR065) that were found to be non-conjugative and non- 
ransformable [ 12 , 14 ]. However, pCAC13a, pAB18PR065 [14] , pAb- 
CR4.3 [13] and pEH_mcr4.3 [14] contain an IS 3 family trans- 
osase (IS Aba19 ) and a Tn 3 family transposase (IS Psy42 ), which 
ould possibly assist in translocation of the gene to the chromo- 
ome or other plasmids. 
Previously, only mcr-1 and mcr-9.1 genes have been reported 
n Enterobacterales isolates in southern Africa. Detection of mcr- 
.3 in other Gram-negative bacterial species suggests that mcr-4.3 
s not limited to China, Singapore, the Czech Republic and Brazil 
Y. Snyman, S. Reuter, A.C. Whitelaw et al. Journal of Global Antimicrobial Resistance 25 (2021) 102–106 
Fig. 1. Plasmid characterisation of the mcr-4.3 -encoding plasmid (pCAC13a) from Acinetobacter baumannii CAC13. The inner rings represent four other known A. baumannii 
mcr-4.3 -encoding plasmids: pAB18PR065 (25 602-bp; CP038265 ); pEC_mcr4.3 (43 093-bp; MK360916 ); pAb-MCR4.3 (35 502-bp; CP033872 ); and pEH_mcr4.3 (18 786-bp; 
CP038261 ). 
Table 1 
Effect of recombinant mcr-4.3 (in pET-48b) and pCAC13a plasmid curing on the colistin minimum inhibitory concentration (MIC) deter- 
mined by broth microdilution 
Isolate Colistin MIC (mg/L) [category a ] 
Escherichia coli ATCC 25922 (susceptible control) 0.5 [S] 
E. coli NCTC® 13846 ( mcr-1 control) 4 [R] 
Acinetobacter nosocomialis CAC13 16 [R] 
E. coli SHuffle® T7 0.5 [S] 
pET-48b( + )-SHuffle® T7 0.5 [S] 
pET-48b( + )- mcr-1 -SHuffle® T7 4 [R] 
pET-48b( + )- mcr-4.3 -SHuffle® T7 0.5 [S] 
Plasmid-cured CAC13 ( mcr-4.3- negative) 1 [S] 
Uncured CAC13 ( mcr-4.3- positive) 16 [R] 




























nd may be disseminated worldwide [ 13 , 34–36 ]. Other mcr vari- 
nts may also be present in southern Africa and intensive clinical 
urveillance is necessary to unearth these and pre-empt further es- 
alation. 
. Conclusion 
This study describes the first report of a plasmid-mediated mcr- 
.3 gene in a colistin resistant clinical isolate from Africa. The mcr- 
.3 gene is encoded on a RepB plasmid in a clinical ST279 A. noso- 
omialis isolate. The pCAC13a plasmid containing mcr-4.3 conferred 
olistin resistance in the A. nosocomialis isolate, although recombi- 
ant mcr-4.3 did not confer resistance in E. coli , suggesting that 
olistin resistance is dependent on the native genomic environ- 
ent of the pCAC13a plasmid or on the bacterial species. 
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